Second-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. (2022)
Attributed to:
Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II)
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-022-32264-6
PubMed Identifier: 35970827
Publication URI: http://europepmc.org/abstract/MED/35970827
Type: Journal Article/Review
Volume: 13
Parent Publication: Nature communications
Issue: 1
ISSN: 2041-1723